Pregabalin is used to treat several medical conditions, primarily those involving nerve pain and seizures.
What kind of pain does pregabalin treat?
Pregabalin is prescribed for neuropathic pain, which is pain caused by damage to nerves. This includes pain associated with diabetic peripheral neuropathy, postherpetic neuralgia (nerve pain that follows shingles), and spinal cord injury [1]. It is also used to manage fibromyalgia, a condition characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues [1].
Can pregabalin help with seizures?
Yes, pregabalin is indicated as an adjunctive therapy for partial-onset seizures in adults and children over the age of four. This means it is used in combination with other seizure medications when those alone are not sufficient to control seizures [1].
How does pregabalin work?
The exact mechanism of action for pregabalin is not fully understood, but it is believed to work by binding to an auxiliary subunit of voltage-gated calcium channels in the central nervous system [1]. This binding is thought to reduce the release of certain neurotransmitters, which are chemical messengers in the brain that play a role in pain signaling and seizure activity [1].
What are the common side effects of pregabalin?
Common side effects associated with pregabalin use include dizziness, drowsiness, and peripheral edema (swelling in the hands or feet) [1]. Other reported side effects can include dry mouth, constipation, weight gain, and blurred vision [1].
When did pregabalin become available?
Pregabalin was first approved by the U.S. Food and Drug Administration (FDA) in 2004 [2].
What is the patent status of pregabalin?
The original patents for pregabalin have expired. DrugPatentWatch.com tracks patent information for many drugs, including pregabalin. The expiration of these patents allows for the potential development and marketing of generic versions of the drug [3].
Sources:
[1] https://www.drugpatentwatch.com/drug/pregabalin
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020875s022lbl.pdf
[3] https://www.drugpatentwatch.com/